• EU Panel Recommends Approval of Zykadia as First-line Treatment for ALK-Positive NSCLC
  • Ventilation Holes in Cigarette Filters Have Increased Lung Cancer, Study Reports
  • Phase 3 Trial Shows Promising Results for Imfinzi in Subset of NSCLC Patients
  • Alunbrig Shows Promise in Certain Advanced NSCLC Patients with ALK Mutations, Study Reports
  • FDA Puts Keytruda on Accelerated Approval Track as Combo Lung Cancer Treatment
  • Clinical Trial to Test Biocept’s Target Selector Platform as Diagnosis, Monitoring Tool for Lung Cancer
  • Tagrisso Helps Lung Cancer Patients Whose Disease Resisted Other Therapies, Trial Shows
  • Takeda’s Alunbrig Receives FDA Accelerated Approval for Treatment of ALK+ Lung Cancer
  • AbbVie’s Veliparib Combo Trial Fails to Improve Lung Cancer Patients’ Survival
  • First NSCLC Patient Dosed in Keytruda and Immunotherapy Combo Phase 1/2 Trial
  • Tagrisso Receives Full FDA Approval for Treatment of T790M-positive NSCLC
  • DelMar’s New Chemotherapeutic VAL-083 Shows Promise in TKI-resistant NSCLC